Issues
-
Cover Image
Cover Image
Low carbohydrate, high protein diets slow/prevent cancer. Mice fed low carbohydrate (Carbs), high protein diets have lower insulin (Ins) and blood glucose levels than mice on Western-like diets. If these mice are injected with tumor cells or are genetically predisposed to mammary tumors, the growth rate or incidence, respectively, of their tumors is significantly reduced. Moreover, these low Carb, high protein diets reduce tumor growth in an additive fashion when combined with the mTOR inhibitor CCI-779 or the COX-2 inhibitor Celebrex. For details, see the article by Ho and colleagues on page 4484 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
Perspective
Meeting Report
Priority Reports
Microenvironment and Immunology
Molecular and Cellular Pathobiology
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
Hedgehog-Producing Cancer Cells Respond to and Require Autocrine Hedgehog Activity
Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network
Prevention and Epidemiology
Therapeutics, Targets, and Chemical Biology
MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
Tumor and Stem Cell Biology
Tumor Suppressor miR-22 Determines p53-Dependent Cellular Fate through Post-transcriptional Regulation of p21
HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells
Targeted Methylation of Two Tumor Suppressor Genes Is Sufficient to Transform Mesenchymal Stem Cells into Cancer Stem/Initiating Cells
Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.